Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R Franks

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Cancer Treatment Reviews|March 1, 1991
Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reductionJ Koning, P Palmer, C R Franks, et al.
Tumori|December 31, 1991
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patientsS Spinazzé, S Viviani, P Bidoli, et al.
Cancer Treatment Reviews|June 1, 1989
Some theoretical and practical limitations of interleukin-2. Ten cases of advanced breast cancer treated with continuous infusion of IL-2L Israel, V Cour, I Pihan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2M E Gore, E Galligioni, C W Keen, et al.
Cancer Biotherapy|January 1, 1993
The impact of interleukin-2 on survival in renal cancer: a multivariate analysisM Jones, T Philip, P Palmer, et al.
Cancer Biotherapy|January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II StudyJ Atzpodien, H Kirchner, P de Mulder, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicityK G Park, S D Heys, J B Murray, et al.
Cancer Research|August 1, 1975
Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed miceE J Stanbredge, L R Boulger, C R Franks, et al.
British Journal of Cancer|December 1, 1992
Interleukin 2 therapy in cancer: identification of respondersJ Broom, S D Heys, P H Whiting, et al.
Anticancer Research|May 1, 1992
Evaluation of the safety of recombinant interleukin-2 (rIL-2) and rIL-2 plus 5-fluorouracil (5-FU) in the adjuvant treatment of gastric cancer patientsS S Ubhi, J Hollingworth, T Horsburgh, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Cancer Treatment Reviews|March 1, 1991
Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reductionJ Koning, P Palmer, C R Franks, et al.
Tumori|December 31, 1991
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patientsS Spinazzé, S Viviani, P Bidoli, et al.
Cancer Treatment Reviews|June 1, 1989
Some theoretical and practical limitations of interleukin-2. Ten cases of advanced breast cancer treated with continuous infusion of IL-2L Israel, V Cour, I Pihan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2M E Gore, E Galligioni, C W Keen, et al.
Cancer Biotherapy|January 1, 1993
The impact of interleukin-2 on survival in renal cancer: a multivariate analysisM Jones, T Philip, P Palmer, et al.
Cancer Biotherapy|January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II StudyJ Atzpodien, H Kirchner, P de Mulder, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicityK G Park, S D Heys, J B Murray, et al.
Cancer Research|August 1, 1975
Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed miceE J Stanbredge, L R Boulger, C R Franks, et al.
British Journal of Cancer|December 1, 1992
Interleukin 2 therapy in cancer: identification of respondersJ Broom, S D Heys, P H Whiting, et al.
Anticancer Research|May 1, 1992
Evaluation of the safety of recombinant interleukin-2 (rIL-2) and rIL-2 plus 5-fluorouracil (5-FU) in the adjuvant treatment of gastric cancer patientsS S Ubhi, J Hollingworth, T Horsburgh, et al.
Pageof 10